Rezurock (Belumosudil Mesylate) Patent Expiration, LOE Window & CMS Spending

Rezurock (Belumosudil Mesylate) by Sanofi: FDA Orange Book core substance LOE 2034-06-20 (last listed 2042-07-14), 0 AB generics, $274.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSanofi
FDA Application & PathwayN214783 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-06-20
Last Listed Patent or Exclusivity Date2042-07-14
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$274.9M
2024 Medicare Part D Spend$242.9M
2024 Medicaid Spend$32.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.